Sara Notararigo

Dr. Sara Notararigo

Health Research Institute of Santiago de Compostela Foundation
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SNSara Notararigo
Sara Notararigo
MNMontserrat Nácher-Vázquez
Montserrat Nácher-Vázquez
IIIdoia Ibarburu
Idoia Ibarburu
MWMª Laura Werning
Mª Laura Werning
PPPilar Fernández de Palencia
Pilar Fernández de Palencia
APAlicia Prieto
Alicia Prieto

1 November 2014 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SNSara Notararigo
Sara Notararigo
MCMateo de Las Casas-Engel
Mateo de Las Casas-Engel
PPPilar Fernández de Palencia
Pilar Fernández de Palencia
ACAngel L. Corbí
Angel L. Corbí
PGpaloma López García
paloma López García

1 May 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JMJ. Alberto Marco
J. Alberto Marco
JGJorge García-Pla
Jorge García-Pla
MCMiguel Carda
Miguel Carda
JMJuan Murga
Juan Murga
EFEva Falomir
Eva Falomir
IBIsabel Barasoain
Isabel Barasoain

28 September 2009 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
SDSilvia Anthoine Dietrich
Silvia Anthoine Dietrich
RLRenate Lindauer
Renate Lindauer
CSClaire Stierlin
Claire Stierlin
JGJürg Gertsch
Jürg Gertsch
RMRuth Matesanz
Ruth Matesanz
KAKarl-Heinz Altmann
Karl-Heinz Altmann

21 May 2021 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
SNSara Notararigo
Sara Notararigo
MMManuel Martin-Pastor
Manuel Martin-Pastor
JVJuan E. Viñuela-Roldán
Juan E. Viñuela-Roldán
AQAdriano Quiroga
Adriano Quiroga
JDJ. Enrique Dominguez-Munoz
J. Enrique Dominguez-Munoz
MAManuel Barreiro-De Acosta
Manuel Barreiro-De Acosta
Inflammatory bowel disease is a multifactorial etiology, associated with environmental factors that can trigger both debut and relapses. A high level of tumor necrosis factor-α in the gut is the main consequence of immune system imbalance. The aim of treatment is to restore gut homeostasis. In this study, fresh blood and serum samples were used to identify biomarkers and to discriminate between Crohn’s disease and ulcerative colitis patients under remission treated with anti-TNF. Metabolomics based on Nuclear Magnetic Resonance spectroscopy (NMR) was used to detect unique biomarkers for each class of patients. Blood T lymphocyte repertories were characterized, as well as cytokine and transcription factor profiling, to complement the metabolomics data. Higher levels of homoserine-methionine and isobutyrate were identified as biomarkers of Crohn’s disease with ileocolic localization. For ulcerative colitis, lower levels of creatine-creatinine, proline, and tryptophan were found that reflect a deficit in the absorption of essential amino acids in the gut. T lymphocyte phenotyping and its functional profiling revealed that the overall inflammation was lower in Crohn’s disease patients than in those with ulcerative colitis. These results demonstrated that NMR metabolomics could be introduced as a high-throughput evaluation method in routine clinical practice to stratify both types of patients related to their pathology.Key messages: NMR metabolomics is a non-invasive tool that could be implemented in the normal clinical practice for IBD to assess beneficial effect of the treatment. NMR metabolomics is a useful tool for precision medicine, in order to sew a specific treatment to a specific group of patients. Finding predictors of response to IFX would be desirable to select patients affected by IBD. Immunological status of inflammations correlates with NMR metabolomics biomarkers.

1 January 2016
Verified
Book Chapter
Closed access
APAdrian Pérez-Ramos
Adrian Pérez-Ramos
MNMontserrat Nácher-Vázquez
Montserrat Nácher-Vázquez
SNSara Notararigo
Sara Notararigo
PGpaloma López García
paloma López García
MMMª Luz Mohedano
Mª Luz Mohedano